Antiverse’s Post

↓ How to discover antibodies for challenging targets ↓ We developed an AI-driven antibody design platform for GPCRs and other challenging targets. Learn more about how our technology works in these short panels. #artificialintelligence #biologics #techbio

Antiverse is sponsoring the Antibody Therapeutics and AI Drug Discovery hubXchange events next week! We're excited to be speaking with potential partners and collaborators. Join us and hear about our developments in AI and antibody discovery for challenging targets. #AdvancedTherapiesXchange #AIDrugDiscoveryXchange #antibodydiscovery

‘Inflammaging’ has pulled the attention of ageing researchers, like a friend walking into a fancy-dress party in normal clothes. What is it and why should you know about it? Age-related inflammation (or Inflamm-Aging) is persistent, low level inflammation that contributes to ageing. The discovery has prompted researchers to begin identifying druggable targets as anti-ageing strategies. It is a complex topic with many different causes, but here is a brief summary: As our cells get older, they stop dividing and linger in the body. These aged cells impede tissue function and promote chronic inflammation, so the immune system works hard to remove them. However, our immune cells also age and become less effective at destroying aged cells. This causes aged cells to accumulate, causing more inflammation and therefore more damage. Inflammaging is a fraction of the complex ageing process, but what makes inflammaging especially important, however, is that it links many ageing processes together. By reducing this inflammation, it may slow down many other drivers of ageing. However, research is yet to confirm whether this is feasible, as there is debate on whether inflammaging is a beneficial or harmful process. Lastly, you might be curious: What can you do now to reduce inflammaging? Surprisingly, most of the advice we found you’ve likely heard before: sleep well, reduce stress, exercise and eat healthy! 🏃🥗🛏️

Rahmad Akbar is the most inspirational figure in antibody design we have met. Rahmad entered antibody design to create therapies that let people be the best versions of themselves. He has cultivated knowledge in data science and machine learning, joining Victor Greiff's lab at the University of Olso in 2018. In 2023, he joined Novo Nordisk as a senior data scientist in antibody design. His passion for collaboration and education is a defining feature of this episode, making this episode informative and inspiring for anyone working in drug discovery. Don't miss this informative chat on how #artificialintelligence can create new possibilities in antibody design, hosted by Murat Tunaboylu, Co-Founder and CEO of Antiverse. Link: https://lnkd.in/em9xnPCa YouTube: https://lnkd.in/ey5tK2ZR #FODD #antibodydiscovery 

This Month's Newsletter: ⭐ How obesity drugs pushed Novo Nordisk and Eli Lilly to the top of the global pharmaceutical rankings.  ⭐ Our most recent Future of Drug Discovery podcast episode. ⭐ Short explanations of all the important events in #antibodydiscovery this month. Let us know your thoughts! Antiverse #pharma #drugdiscovery

What happened in #antibodydiscovery this month? ⬇️ 𝗔𝘂𝗴 𝟱𝘁𝗵: Bristol Myers Squibb terminates $1.5B bispecific antibody programme with Agenus in strategic realignment.  https://lnkd.in/eEGbgKHH 𝗔𝘂𝗴 𝟲𝘁𝗵: Merck enters co-development with Daiichi Sankyo for tri-specific T-cell engager for lung cancers.  https://lnkd.in/gH3y8u8v 𝗔𝘂𝗴 𝟴𝘁𝗵: Exscientia merges with Recursion, with 10 clinical results expected over the next 18 months.  https://lnkd.in/eis3bRAD 𝗔𝘂𝗴 𝟵𝘁𝗵: Merck & Co. secures global rights to Curon Biopharmaceutical's blood cancer bi-specific antibody in a $700M deal.  https://lnkd.in/g6w3gihR 𝗔𝘂𝗴 𝟮𝟬𝘁𝗵: Merck & Co. adjusts its oncology pipeline in ADC switch with Kelun Biotech in a $37.5M deal.  https://lnkd.in/e4EtKGRv 𝗔𝘂𝗴 𝟮𝟭𝘀𝘁: Regeneron's linvoseltamab, a blood cancer bispecific, is delayed by the FDA over a manufacturing problem.  https://lnkd.in/eceBZ-vt Follow Antiverse: we design antibodies for challenging targets. #pharma #biotech

The market for weight-loss drugs is expanding rapidly, with projections estimating it will reach $105 billion by 2030. This growth partly is driven by the increasing prevalence of obesity, with nearly half of the world's population expected to be classified as obese or overweight by 2023 (World Obesity Federation). However, there have also been a series of interesting developments in pharmaceutical companies: In 2017, Novo Nordisk, Europe's most valuable company, launched 'Ozempic', which was developed for treating type 2 diabetes. It was then repurposed for treating obesity as 'Wegovy' in 2021 following studies confirming the dramatic weight-loss effects of the drug. Eli Lilly's 'Zepbound' (for weight-loss), launched in December 2023, emerged as a strong competitor, taking advantage of Novo's underestimation of supply demands. Many other companies, including Amgen, Roche, and AstraZeneca, have swiftly followed in developing their own obesity treatments, aiming to reduce the inconvenience of administrating an injection once per week and addressing significant side effects. These remarkable developments in the weight-loss drug space has put diabetes and obesity treatments on track to become the best-selling drug class of all time. As the landscape of diabetes and obesity treatments evolves, it is crucial to consider the profits generated from these largely preventable diseases. The unprecedented growth of the weight-loss drug market should prompt strategic action across multiple industries to start addressing the root causes of these diseases. This should not, however, overshadow the significant benefits weight-loss drugs could bring in alleviating the strain on healthcare services. This concludes our summary on Weight-Loss Drugs (so far)! #pharma #obesity #drugdiscovery